Soo M S
Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA.
South Med J. 1998 Nov;91(11):994-1000. doi: 10.1097/00007611-199811000-00001.
Screening mammography programs have contributed to an overall decline in breast cancer mortality. The screening process, however, also results in detection and biopsy of many nonpalpable lesions that eventually prove to be benign, contributing to the burden of costs to our health care system. Percutaneous imaging-guided core biopsy has proven to be a safe and accurate technique for obtaining a histologic diagnosis in most patients who have screening-detected lesions; it is done at lower cost with lower resultant morbidity to the patient compared with traditional surgical excisional biopsy. I review the indications, techniques, method of correlating the histology with mammographic findings, and accreditation requirements for imaging-guided core biopsies of the breast done under mammographic (ie, stereotactic) or sonographic guidance.
乳腺钼靶筛查项目有助于总体降低乳腺癌死亡率。然而，筛查过程也会导致许多不可触及的病变被检测出来并进行活检，而这些病变最终被证明是良性的，这增加了我们医疗保健系统的成本负担。经皮影像引导下的粗针活检已被证明是一种安全、准确的技术，可用于大多数筛查发现病变的患者以获得组织学诊断；与传统手术切除活检相比，它的成本更低，给患者带来的发病率也更低。我将回顾乳腺钼靶（即立体定向）或超声引导下乳腺影像引导粗针活检的适应证、技术、组织学与钼靶检查结果的关联方法以及认证要求。
